T2-weighted MRI-based radiomics for preoperative prediction of homologous recombination deficiency status in high-grade serous ovarian carcinoma
Abdominal Radiology · 03.11.2026
DOI: 10.1007/s00261-026-05858-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, online erschienen am 03.11.2026. Verfasst von Jianan Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Rationale and objectives The aim of this study was to explore the feasibility of T2-weighted imaging (T2WI) - based radiomics in preoperative prediction of homologous recombination deficiency (HRD) status in patients with high-grade serous ovarian carcinoma (HGSOC), and to establish a non-invasive approach for guiding individualized treatment planning. Materials and methods A total of 133 patients with pathologically confirmed HGSOC who underwent MRI scan (T2WI, T1-contrast enhanced) were retrospectively enrolled in this study. All patients were stratified into HRD-positive and HRD-negative group. These 133 patients (41 in HRD-negative group and 92 in HRD-positive group) were randomly allocated to a training set ( n = 93) and a validation set ( n = 40) at a 7:3 ratio. Three different models were constructed and evaluated: clinical characteristics only (clinical model); T2WI-radiomics features only (radiomics model); and a combination of them all (combined model). The predictive performance was evaluated using the receiver operating characteristic (ROC) analysis, and area under the curves (AUCs) were compared using the DeLong test. Calibration curves and decision curve analysis (DCA) were applied to validate the clinical-radiomic combined model.
Results
In the training set, the combined model achieved the best performance (AUC = 0.889; all P > 0.05). The radiomics model achieved predictive performance comparable to the clinical model (AUC of 0.762 vs. 0.790; P = 0.676). In the validation set, the combined model performed significantly better than the clinical or radiomics model (AUCs of 0.853 vs. 0.805 vs. 0.706; all P > 0.05). DCA demonstrated that the combined model achieved superior net benefit across a wide range of threshold probabilities compared with the clinical and radiomics models alone.
Conclusions
Our research demonstrated that the combined model achieved the optimal predictive performance. It is feasible to apply radiomics to predict HRD status of HGSOC patients, which can further assist clinicians in formulating individualized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiology, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
- Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China. zouyuzju@zju.edu.cn.
ORCID-Profile: Jianan Zhou
Zitieren
APA
Zhou, J., Jiang, X., Deng, M., Li, K., Shen, Y., & Zou, Y. (2026). T2-weighted MRI-based radiomics for preoperative prediction of homologous recombination deficiency status in high-grade serous ovarian carcinoma. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05858-7
Vancouver
Zhou J, Jiang X, Deng M, Li K, Shen Y, Zou Y. T2-weighted MRI-based radiomics for preoperative prediction of homologous recombination deficiency status in high-grade serous ovarian carcinoma. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05858-7
BibTeX
@article{Zhou2026,
author = {Zhou, Jianan and Jiang, Xinang and Deng, Meixiang and Li, Kui and Shen, Yuanming and Zou, Yu},
title = {T2-weighted MRI-based radiomics for preoperative prediction of homologous recombination deficiency status in high-grade serous ovarian carcinoma},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05858-7}
}
EUVIMED